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OBJECTIVES: Obtaining access to HIV/AIDs medications can be a challenge for
low-income people with HIV who currently cannot obtain Medicaid benefits be-
cause they are considered too healthy for assistance but too poor to purchase
coverage on their own. We would like to evaluate the current level of access to
medication for uninsured individuals living with HIV/AIDs and assess how access
to these drugs might change over time. METHODS: We limited the scope of our
review to the top ten US states with the largest HIV/AIDs populations: New York,
California, Florida, Texas, Georgia, New Jersey, Pennsylvania, Illinois, Maryland,
and Massachusetts. We then reviewed the current structure of their AIDs Drug
Assistance Programs (ADAPs) and evaluated the robustness of the benefit and its
respective formulary. Our next step was to then project how this populationmight
benefit from the expansion of Medicaid. RESULTS: New York and California have
some of the most comprehensive benefits covering 465 and176 HIV/AIDS-related
medications, respectively. Texas, on the other hand, appears to be themost restric-
tive, covering only 44 medications. Looking forward, some states could see larger
increases in the number of uninsured HIV/AIDS patients that now fall under their
Medicaid programs. Texas, Virginia, and North Carolina could potentially see up-
wards of a 35% increase in Medicaid enrollees with HIV/AIDs. CONCLUSIONS: Half
of the states reviewed have waiting lists for their ADAPs and two of the states have
already extended Medicaid benefits to AIDs/HIV patients via a 1115 waiver. To that
end, it seems reasonable to conclude that while the expansion of Medicaid will
generally be beneficial for the uninsured living with HIV/AIDs, it’s impact will be
felt more so in some states while not as much in others.
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OBJECTIVES: The study aimed to assess availability and stock outs of antimalarial
drugs in public and private secondary health care facilities in two cities of Pakistan;
Islamabad (Federal capital) and Rawalpindi (twin city).METHODS: A comparative,
cross-sectional study was designed to evaluate anti-malarial drugs stock outs in
public and private secondary health care facilities in the two cities. The anti-ma-
larial drugs records were collected from the pharmacies located in the health care
facilities. Pre-validated tools i.e., WHO facility indicator form and USAID inventory
indicator and drug stock outs form were used to collect data regarding availability
and stock outs of anti-malarial drugs. After the data collection, data were coded
and analyzed by using SPSS version 16. RESULTS: The total average number of
day’s stock out of anti-malarial drugs at public secondary healthcare facilities was
230.3 and 291.9 days in Islamabad and Rawalpindi respectively. While on the other
hand total average number of day’s stock out of anti-malarial drugs at private
secondary health care facilities was 170.2 and 210.4 days in Islamabad and Rawal-
pindi cities, respectively. A pharmacist wasmostly available in all the public health
care facilities but in few of the private health care facilities. Moreover a significant
difference (p  0.05) was noted in anti malarial drug stock outs among different
public and private healthcare facilities in the two cities. CONCLUSIONS: The find-
ings suggest major stock outs of anti-malarial drugs in both public and private
health care facilities; however the situation was more prevalent in the public sec-
tor. Essential drug list was not available and being followed. The role of pharmacist
comes under question in effective drug management in public health care facili-
ties.
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OBJECTIVES:This study compared pneumonia-related rehospitalizations and total
medical costs among patients hospitalized for pneumonia and treated with lin-
ezolid or vancomycin post-discharge.METHODS: Two administrative claims data-
bases were pooled and adults hospitalized for pneumonia and treated with lin-
ezolid or vancomycin post-discharge from January 1, 2007 through September 30,
2009 were identified. Two pneumonia populations were studied: 1) “broad group”
that included all pneumonia ICD-9 codes; and 2) “narrow group” that included
ICD-9 codes consistentwith the FDA labeled pneumonia indication.Within 42 days
following hospital discharge, pneumonia-related rehospitalizations and totalmed-
ical costs were compared between linezolid and vancomycin users. Multivariable
regression analyseswere performed, controlling for index hospitalization length of
stay, clinical and demographic factors. RESULTS: The “broad group” consisted of
1,468 patients (46% linezolid), while 417 patients (61% linezolid) met the “narrow”
ICD-9 code criteria. Unadjusted pneumonia-related rehospitalization rates were
lower for linezolid relative to vancomycin in both the “broad” (9% vs. 15%, p 0.01)
and “narrow” (6% vs. 15%, p  0.01) groups. In the multivariate analysis, linezolid
users were less likely to have a pneumonia-related rehospitalization in both the
“broad” (OR0.59, 95%CI: 0.42 – 0.83) and “narrow” (OR0.34, 95%CI: 0.17 – 0.69)
populations. Adjusted total costs were significantly lower for linezolid users in the
“broad” population (cost savings: $1525; 95%CI: $1423 - $1627). No significant dif-
ference in cost savings was observed in the “narrow” population (adjusted point
estimate of cost savings with linezolid: $341; p  0.63). CONCLUSIONS: Among
commercially insured patients treated with either linezolid or vancomycin follow-
ing hospitalization for pneumonia, linezolid was associated with significantly
lower pneumonia-related re-hospitalizations and total direct medical costs in the
“broad” population of all pneumonia patients. In the narrower, FDA labeled-indi-
cation group, significantly lower pneumonia-related re-hospitalizations occurred
among linezolid users but the between-treatment difference in total adjustedmed-
ical costs was not significant.
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OBJECTIVES: Aims of this study were to quantify the expenditure for antiretroviral
(ARV) treatment in Italy, and to estimate the potential impact of the introduction of
generic antiretrovirals in the Italian pharmaceutical market. METHODS: Using a
data-set of pharmaceutical expenditure in Italy, we analysed the total expenses for
ARVs at national level. Since in the near future generic zidovudine (AZT), lamivu-
dine (3TC), nevirapine (NVP) and efavirenz (EFV) will be available in Italy, we cal-
culated the potential cost-saving, modeling scenarios with price reduction be-
tween 20%-60% of the originators prices. In sensitivity analyses, we assumed that
branded emtricitabine could be substituted by generic 3TC, and that fixed dose
combinations (FDC) could be partially substituted by single components with ge-
neric medicines. RESULTS: In 2010, €500.689.927 were spent for antiretroviral ther-
apies (total ARV use: 1.91 DDIs/1000 inhabitants/day), with an increase of 12.6%
compared with the 2009 expenditure. The most relevant proportion was attribut-
able to FDC, accounting for €238.826.599 (47.7% of total costs). The total percentage
of costs for ARVs related to the use of AZT, 3TC, NVP and EFV was 7.33%
(€36.713.056). Assuming the prescriptions of these drugs to be constant in next
years, different scenarios of price reduction (from 20% to 60%) for generic drugs
showed an estimated cost-saving ranging from €7.342.611 (1.47% of total ARV costs)
to €22.027.833 (4.40%). When including emtricitabine substitution by 3TC, cost-
saving rises to €7.435.738-22.307.213 (1.49-4.46%) and to €26.832.726-80.498.178
(5.36-16.08%) considering the unbundling of branded FDC. CONCLUSIONS: The
forthcoming availability of some antiretroviral generics could be an option for
safely and effectively cost-saving. However, in our study, the greater reduction of
costs has been estimated by FDC substitution, raising the potential dilemma of
increasing regimen complexity. Further studies will be needed to evaluate safety
and efficacy of FDC substitutionwith generics incorporating both treatment adher-
ence and pharmacoeconomic outcomes.
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OBJECTIVES: Despite recent advances in critical care, severe sepsis is one of the
world’s leading causes of death and remains both an important clinical challenge
and an economic burden to western health care systems. Our aim is to analyze the
costs and discharge status of severe sepsis in Spain and to examine the impact of
age in terms of hospital outcomes METHODS: Analysis of the 2008 nationwide
hospital discharge database. We identified cases based on the ICD-9-CM codes for
sepsis and organ dysfunction. We examined demographics, comorbidities, clinical
outcomes and hospital costs and performed a logistic regression analysis to iden-
tify factors associated with in-hospital mortality. We calculated hospital charges
based on the National Health Service charges for DRGs. To depict the amount of
resources spent to procure a given level of desired outcome (hospital survival) we
also determined the cost per survivor. RESULTS: A total of 37,746 cases were ana-
lyzed. Median age was 73 year (p25:59; p75:82); 58% were men, 28% surgical cases,
31% of cases had no associated comorbidity. In-hospital mortality was 45%. An
inverse relationship between survival rate and age was consistently observed after
adjusting by other clinical variables. Total costs of hospitalizations exceeded €500
million with 35% spent in patients aged 74 years. Age-related costs per survivor
were €19,538 in cases aged 1 year; €12,390 in those aged 1-14 years; €16,703 in
patients aged 15-44 years; €15,917 in patients 45-64 years, €13,828 in patients 65-74
years and €9,366 in those aged74 years. CONCLUSIONS: Severe sepsis associates
with highmortality and hospital-resources utilization. Age has a significant impact
on outcomes both from clinical and economic perspectives. Age is an independent
predictor of mortality. Costs per survivor, however, are substantially lower in el-
derly patients. These data will help inform health care decision-making and re-
source planning in the face of an ageing population.
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OBJECTIVES: The Human Papillomavirus (HPV) infection is the most common sex-
ually transmitted disease in the United States. HPV infected males also put their
female partners at increased risk of cervical cancer. Recently a HPV vaccine was
approved for use in males aged 9-26 years. The purpose of this study was to assess
awareness regarding HPV and the vaccine amongst a cohort of male university
students. Further, we evaluated their attitude towards the HPV vaccine and its
relationship with awareness. METHODS: A self-administered anonymous survey
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was administered to a sample ofmale university students aged 18-26 years. Patient
characteristics measured included education, race, major, marital/relationship
status and insurance status. Awareness regarding HPV and the vaccine, and atti-
tude towards willingness to get vaccinated, perceived risks of being infected with
HPV, and benefits of the vaccine weremeasured using a 5 point Likert scale. Coded
data were analyzed by conducting descriptive and correlation analysis using SAS
9.2. RESULTS: A total of 203 completed surveys were obtained. Mean (SD) age of
participants was 21.56 (2.44) years. Mean awareness scores were high for HPV
(3.89  1.34) and HPV vaccine (3.55  1.30). Mean attitude scores were somewhat
mixed for willingness to get vaccinated (2.89  1.10), benefit of vaccination (3.18 
1.04), and at risk of getting HPV (3.15 1.21). There was no significant co-relation-
ship between attitude and awareness variables. Willingness to get vaccinated was
negatively correlated with perceived risk (r0.15, p 0.05) and vaccination benefit
(r0.34, p0.05). CONCLUSIONS: Despite awareness regarding HPV and HPV vac-
cine a large proportion of the cohort was not willing to get vaccinated. This may be
due to the perception of not being at risk of getting infected and not having a clear
understanding of the benefits of vaccination.
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OBJECTIVES: Despite it=s importance, there are few published studies describing
the burden of pneumococcal disease in elderly population of developing countries.
The goal of this study is to estimate the burden of pneumococcal diseases inMexico
in people 50 years.METHODS: Mortality due to pneumonia, bacteremia, menin-
gitis and acute otitis media (AOM) in patients 50 years was extracted from Mex-
ican MoH official databases (2009 data, ICD-10 classification). Population structure
was extracted from the Mexican official source. Incidence and prevalence of pneu-
mococcal disease were extracted from published sources. Mortality was adjusted
according to the proportion of deaths attributable to pneumococcal disease (from
literature). Data were analyzed with DISMOD II software (to produce consistent
estimates for epidemiological parameters of pneumococcal disease). Presence and
type of comorbidities were taken in account: low risk: without comorbidities; mild
risk: congestive heart failure, valvular disease, valvular disorders, pulmonary hy-
pertension, peripheral vascular disease, hypertension, ischemic heart disease,
stroke, COPD, diabetes mellitus, chronic renal failure, chronic liver disease, use of
tobacco and alcohol abuse; high risk: comorbidities associated to HIV/AIDS, lym-
phoma, tumors, splenic disease and sickle cell anemia. RESULTS: For 2009 were
estimated 12,798 cases ofmeningitis, where 86% of patients had low risk and 13%had
moderate risk of comorbidity, mortality rate was 1.6 per 100,000 inhabitants. For out-
patient pneumonia 4,275 cases were estimated, 53% low risk and 46% mild risk. For
inpatient pneumonia 31,631 cases were estimated, 78% low risk and 21% mild risk,
mortality rate: 7.8 per 100,000. For AOM 9,817 cases were estimated (100% low risk).
Meanwhile, 611casesofbacteremiawereestimated, 98%had lowriskand2%hadmild
risk. CONCLUSIONS: The availability of reliable epidemiological parameters regard-
ingpneumococcal disease inMexicanpopulationover 50 could support theevaluation
of current prevention policies, as well as the design of more efficient ones.
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OBJECTIVES: Complicated skin and skin structure infections (cSSSI) are a common
reason for hospitalization. Inappropriate empiric therapy (IAET) for cSSSI prolongs
hospital stay. Patients with a mixed cSSSI (MSI, gram positives [GP] and gram
negatives [GM] present) are at an increased risk for receiving IAET. We set out to
examine the bacteriology and components of IAET coverage inMSI.METHODS:We
conducted a single-center retrospective cohort study of patients hospitalized April
2006 to December 2007 with a cSSSI. IAET was defined as failure to deliver an
antibiotic with in vitro activity against the offending pathogen(s) within 24 hours of
presentation. RESULTS: Of the 717 patients hospitalized with a cSSSI, 158 (22%)
received IAET; 68 (9.5%) had a MSI. Among all MSI, most frequently isolated patho-
gens were methicillin-resistant S. aureus (MRSA) (n23, 33.8%), Streptococcus sp.
(n22, 32.4%) and P. aeruginosa (n21, 30.9%). IAET was noted in 26 (38.2%) MSIs.
Both appropriate GP andGN coverageweremissing in 7 (26.9%) cases.While among
all MSIs treated with IAET Streptococcus sp. coverage was never missing, treatment
for MRSA was absent in 3 (11.5%) cases. Most frequently missing coverage was for
GN (n18, 69.2%), with P. aeruginosa untreated in 6 (23.1%). GP coverage was absent
in 15 (57.7%), most frequently for vancomycin-resistant Enterococcus sp. (VRE) (n9,
34.6%).CONCLUSIONS: In this single-center study, patientswith aMSIwere at high
risk for IAET. Coverage was more frequently left out for GN than for GP, with P.
aeruginosa and VRE frequently remaining untreated empirically.
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OBJECTIVES: In the absence of reminders, multi-dose vaccine completion rates for
adolescents and adults are low. Human papillomavirus (HPV) vaccine completion,
for example, is 32% among US adolescents. In the IMPACT trial (Improving Patient
Adherence through Clinic-initiated Text messages), we examine the efficacy of
automated text message-based reminders in improving series completion rates
among patients 9 years old who have begun, but not completed, one or more
multi-dose vaccine series: hepatitis B (HBV) or HPV.METHODS: In thismulti-center
randomized controlled trial, consenting participants (N334)were assigned during
a clinical visit to receive either 1) text message-based reminders before their next
dose, or 2) traditional appointment reminders. In group 1, text messages were
delivered to patients’ or parents’ cellular telephones using aweb-based application
that automatically sends text reminders prior to appointments dates entered by
clinical staff. We evaluated the association between treatment group and appoint-
ment attendance and vaccine series completion RESULTS: Among all participants,
HPV or HBV series completion within 6 months of enrollment was higher for those
receiving a text messages (39.8 % vs. 32.0%), but with meaningful effect modifica-
tion by age. Among adult patients, those who received a text were more likely to
complete their vaccine series for HPV or HBV (37.5% vs. 24.2%; risk ratio [RR] 1.55).
Among adult patients who initiated the HPV series alone, text messages doubled
the rate of vaccine completion (37.5% vs. 18.5%; RR 2.03). Textmessaging was not
effective for increasing series completion among adolescent participants. Text
messaging improved overall appointment attendance at 3 of the 4 clinical sites, but
the differenceswere not statistically significant.CONCLUSIONS: In this pilot study,
text messaging initiated by the clinical office demonstrated improved multi-dose
vaccine series completion among adult patients and showed promising trends for
reducing appointment no-show rates.
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OBJECTIVES: Research has consistently demonstrated the effectiveness of antiret-
roviral therapy (ART) in reducing HIV-related morbidity and mortality. Current
guidelines for the treatment of HIV identify specific combination regimens with
medications from two different drug classes. The objective of this study was to
assess compliance with these guidelines among treatment-naïve individuals.
METHODS: Mississippi Medicaid prescription claims data (1/2008 10/2011) were
analyzed for beneficiaries who met eligibility criteria: age 17, not pregnant, and
enrolled in Medicaid for at least three months prior to the index prescription date.
Beneficiaries were considered treatment-naïve and starting initial therapy if no
ART claims existed for at least threemonths prior to the first ART claim.Wedefined
a guideline-adherent ART regimen as use of a minimum of three drugs including
two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with one
protease inhibitor (PI) or one nonnucleoside reverse transcriptase inhibitor (NNRTI)
between July 2008 and December 2010. Between January 2010 and November 2011,
a guideline-adherent ART regimen could also include two NRTIs in combination
with one integrase inhibitor. RESULTS: A total of 604 beneficiaries met inclusion
criteria. Between July 2008 and December 2009, 39.8% and 25.5% of beneficiaries
were on an NNRTI-based regimen and PI-based regimen, respectively. Addition-
ally, 4.4%metmore than one guideline simultaneously. Approximately 30.3%were
prescribed a medication regimen that was not in accordance with guidelines. Be-
tween January 2010 and October 2011, 38.8% and 24.1% of beneficiaries were on an
NNRTI-based regimen and PI-based regimen, respectively. Additionally, 5.3% met
more than one guideline simultaneously. Approximately 25.5% were prescribed a
medication regimen that was not in accordance with guidelines. CONCLUSIONS:
During the study period, the majority of beneficiaries were in accordance with
treatment guidelines for initial therapy for treatment-naïve patients withminimal
temporal changes across the three primary combination regimens.
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OBJECTIVES: Streptococcus pneumoniae is responsible for more than a million
deaths globally each year, most of them in the developing world. The burden of S.
pneumoniae infections is highest in children. Estimates in adult population are un-
common. Our objective was to determine the burden of disease, measured in dis-
ability adjusted life years (DALYs), associated with pneumococcus in adults (older
than 15 years of age) in Colombia in 2008.METHODS: Using different data sources
(national mortality records, official registries, published literature and local epide-
miological data) we estimated incidence, mortality and disability due to bacterial
pneumonia, bacterial meningitis and bacteremia of any cause for year 2008, and
the fraction of these that can be attributed to S. pneumoniae. We used Murray’s
standard methodology to estimate DALYs (including age-weighting and discount-
ing at 3%). RESULTS: There were 6488, 1276 and 452 deaths due to pneumonia,
bacteremia andmeningitis, respectively. Incidence rates for these same 3 diseases
(before adjusting for underreporting, that has been estimated in 65%) were 233,814;
999 and 960, respectively. A total of 63,463 DALYs are lost due to S. pneumoniae in
Colombians age 15 or over (55,362DALYs, 87%, due to premature death).Most of the
burden (51,848 DALYs, 81.7%) is due to pneumonia, followed by meningitis (9,241
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